The Cancer Cachexia Market is witnessing steady growth due to the rising prevalence of cancer and the urgent need for effective therapeutic solutions. In 2024, the global market size was valued at USD 2.71 Billion, and it is projected to expand from USD 2.83 Billion in 2025 to reach USD 4.09 Billion by 2033, reflecting a CAGR of 4.7% during the forecast period (2025–2033).
According to the World Health Organization, cancer is the second leading cause of death worldwide, responsible for nearly 9.6 million deaths in 2018. The incidence of cancer is expected to rise significantly, especially in low- and middle-income countries, fueling the demand for cancer cachexia treatment. Cachexia, characterized by unintentional weight loss, muscle wasting, and systemic inflammation, is a critical condition affecting cancer patients globally.
Cancer Cachexia Market Growth Factors
- Increasing Prevalence of Cancer: As per GLOBOCAN 2020, there were 19.2 million new cancer cases and 9.9 million cancer-related deaths worldwide. By 2040, cancer cases are expected to reach 28.8 million, significantly driving the need for cachexia management.
- Strong R&D and Product Pipeline: Companies like Aavogen Inc., Helsinn Group, and various universities are actively conducting clinical trials and developing drugs such as Anamorelin and AVGN7, showing promising results for cachexia treatment.
- Regional Growth:
- North America leads the market due to rising cancer cases and strong healthcare infrastructure.
- Europe follows with increasing cancer prevalence and ongoing clinical trials.
- Asia Pacific is showing rapid growth, led by countries like China and India where cancer cases are rising significantly.
Market Restraining Factors
The biggest hurdle for this market is stringent regulatory requirements. Cancer cachexia drugs, often used for terminally ill patients, face long approval timelines that vary across regions, delaying access to life-improving therapies.
Market Opportunities
Advancements in multi-target treatment strategies such as omega-3 fatty acids (EPA and DHA), ghrelin-based therapies, and ActRIIB pathway inhibitors are creating opportunities for innovative cachexia therapeutics. Research on non-invasive biomarkers is also opening new avenues for early diagnosis and effective treatment.
Key Players in the Cancer Cachexia Market
- Pfizer Inc.
- Helsinn Group
- AAVogen Inc.
- Artelo Biosciences Inc.
- Merck & Co. Inc.
- NGM Biopharmaceuticals
- Aveo Pharmaceuticals Inc.
- Green Cross Wellbeing Corporation
- Cannabics Pharmaceuticals Inc.
- TCI Peptide Therapeutics
- Fresenius Kabi
- Aeterna Zentaris Inc.
- Aphios Corporation
- Bristol-Myers Squibb Company
- Tetra Bio-Pharma
- Actimed Therapeutics
Cancer Cachexia Market Segmentation
- By Therapeutics: Progestogens, Corticosteroids, Combination Therapy, Other Therapeutics
- By Mechanism of Action: Appetite Stimulators, Weight Loss Stabilizers
- By Region: North America, Europe, Asia Pacific, Middle East & Africa, Latin America
🔗 Read Full Report Here: Cancer Cachexia Market Report
About Us
Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.
Contact Us
📧 Email: sales@straitsresearch.com
📞 Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
🌐 Website: https://straitsresearch.com/